论文部分内容阅读
目的回顾性总结及评价手术后确诊的小细胞肺癌(SCLC)患者44例联合放化疗治疗的疗效。方法44例SCLC患者中,Ⅰ期15例(34.1%),Ⅱ期13例(29.6%),Ⅲ期12例(27.3%),Ⅳ期4例(9.1%),除肺段切除1例外均行肺叶或全肺切除,术后均用“依托泊苷+顺铂或卡铂”或“紫杉醇+顺铂或卡铂”方案化疗4～8个疗程,分别随访1,3,5年生存率。结果44例小细胞肺癌(SCLC)患者的1,3,5年总的生存率分别为84.3%、48.2%和18.1%。Ⅰ期、Ⅱ期患者采用术后联合放、化疗,可以获得较好疗效,Ⅲ期、Ⅳ期患者首选手术对生存率无益。结论手术后联合放、化疗对Ⅰ～II期的SCLC具有良好的治疗效果。
Objective To retrospectively summarize and evaluate the efficacy of combined radiotherapy and chemotherapy in 44 patients with small cell lung cancer (SCLC) confirmed after surgery. Methods A total of 44 patients with SCLC were classified into 15 cases (34.1%) in stage Ⅰ, 13 cases (29.6%) in stage Ⅱ, 12 cases (27.3%) in stage Ⅲ and 4 cases (9.1%) in stage Ⅳ, All the patients underwent lobectomy or pneumonectomy and were treated with 4 ~ 8 courses of chemotherapy of “etoposide + cisplatin or carboplatin” or “paclitaxel + cisplatin or carboplatin” after operation, 5-year survival rate. Results The 1, 3, 5-year overall survival rates of 44 patients with small cell lung cancer (SCLC) were 84.3%, 48.2% and 18.1%, respectively. Stage Ⅰ, Ⅱ patients with postoperative combined radiotherapy and chemotherapy, you can get a better effect, stage Ⅲ, Ⅳ patients preferred surgery on the survival rate of no benefit. Conclusion Combined surgery and chemotherapy after operation have good therapeutic effect on stage Ⅰ ~ Ⅱ SCLC.